YD Bio Limited Ordinary Shares (YDES) Revenue History
Annual and quarterly revenue from 2020 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
YDES Revenue Growth
YDES Revenue Analysis (2020–2024)
As of May 8, 2026, YD Bio Limited Ordinary Shares (YDES) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q2 2025) recorded $0 in revenue.
Looking at the longer-term picture, YDES's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $510,360 in 2024, representing a new all-time high.
When compared to Healthcare sector peers including BTBT, NUVB (+1205.5% YoY), and ZLAB (+15.3% YoY). Compare YDES vs BTBT →
YDES Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| YDESCurrent | $0 | - | - | -286.5% | |
 BTBT | $164M | - | - | 16.8% | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
 ZYME | $106M | -15.6% | +22.2% | -87.3% | |
 IQ | $29.2B | -10.6% | +0.2% | 6.2% |
YDES Historical Revenue Data (2020–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $510K | +45.8% | $155K | 30.4% | $-1,461,930 | -286.5% |
| 2023 | $350K | - | $153K | 43.8% | $-9,847 | -2.8% |
| 2022 | $0 | - | $0 | - | $-2,323,153 | - |
| 2021 | $0 | - | $0 | - | $-1,722,364 | - |
| 2020 | $0 | - | $0 | - | $-344,223 | - |
See YDES's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs YDES Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare YDES vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonYDES — Frequently Asked Questions
Quick answers to the most common questions about buying YDES stock.
Is YDES's revenue growth accelerating or slowing?
YDES TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is YDES's long-term revenue growth rate?
YD Bio Limited Ordinary Shares's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is YDES's revenue distributed by segment?
YDES reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.